Tuesday, 31 May 2016

Organ Transplant Immunosuppressant Drugs Market to be suppressed by Dearth of Donor Organs

The global organ transplant immunosuppressant drugs market is exhibiting a CAGR of -5.0% within a forecast period from 2015 to 2023. The market was registered at US$5.1 bn in 2014. It is expected to shrink to US$3.2 bn by the end of 2023, according to a research report released by Transparency Market Research. The report is titled “Organ Transplant Immunosuppressant Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023.” 

Get Free Sample Research Report: 
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1967

According to the report, there are multiple factors restraining the global organ transplant immunosuppressant drugs market. The greatest restraint on this market is the imbalance in the supply and demand chain. Other factors hampering the global organ transplant immunosuppressant drugs market include the high cost of availing the procedure, coupled with unfavorable reimbursement policies, along with the advent of new and more favorable technologies.

Modern medicine has created alternatives to organ transplant immunosuppressant drugs, such as the growing use of stem cells. The market is further restricted by a severe lack of healthy donor organs.
The global organ transplant immunosuppressant drugs market is currently being boosted by the growing incidence of chronic diseases. However, the ratio of healthy donor organs to patients in need is askew, creating large-scale shortages of available organs.

The report provides a segmented analysis of the global organ transplant immunosuppressant drugs market in terms of drug class, transplant, and geography.

In terms of drug classes, the global organ transplant immunosuppressant drugs market was led by the segment of calcineurin inhibitors in 2014. In that year, the segment was calculated at US$2.3 bn. At the same time, a major number of patients are usually prescribed tacrolimus in order to maintain the schedule of the immunosuppression. This procedure shows higher potency as well as a lower rejection rate as opposed to cyclosporine.

Oral prednisone, prednisolone, and methyl prednisolone are the three most common types of corticosteroids utilized during organ transplant. Corticosteroids are usually administered to patients in the initial stages of organ transplantation.

The report’s segmentation based on organ transplant shows that the global organ transplant immunosuppressant drugs market was dominated by the segment of kidney transplants in 2014, when it held over half the market. It is expected that the kidney transplant segment will dominate the market in the given forecast period.

From a geographical perspective, the report reveals North America to have led the global organ transplant immunosuppressant drugs market in 2013. This region has benefitted largely from the high rate of organ transplants in the United States. The U.S. consists of a large number of advanced medical facilities that offer organ transplant procedures. The nation’s healthcare industry also offers advanced surgical procedures and modern and enhanced immunosuppressive drugs. This has led to a high success rate of organ transfer procedures.

The key players in the global organ transplant immunosuppressant drugs market are Pfizer, Bristol-Myers Squibb Company, Sanofi, Novartis, AbbVie, Allergan, and Astellas Pharma.

Full Research Report on Global Organ Transplant Immunosuppressant Drugs Market: 
http://www.transparencymarketresearch.com/organ-transplant-immunosuppressant-drugs.html

No comments:

Post a Comment